Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Q3 2025 value amounting to $32.0 million.

  • Catalyst Pharmaceuticals' Other Operating Expenses rose 1179.51% to $32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.2 million, marking a year-over-year increase of 2007.53%. This contributed to the annual value of $106.2 million for FY2024, which is 2565.89% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Other Operating Expenses is $32.0 million, which was up 1179.51% from $30.0 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Other Operating Expenses' 5-year high stood at $32.0 million during Q3 2025, with a 5-year trough of $4.5 million in Q2 2021.
  • For the 5-year period, Catalyst Pharmaceuticals' Other Operating Expenses averaged around $17.8 million, with its median value being $20.5 million (2023).
  • In the last 5 years, Catalyst Pharmaceuticals' Other Operating Expenses surged by 978.26% in 2021 and then soared by 17974.53% in 2023.
  • Catalyst Pharmaceuticals' Other Operating Expenses (Quarter) stood at $7.3 million in 2021, then soared by 60.25% to $11.8 million in 2022, then surged by 111.19% to $24.9 million in 2023, then grew by 24.61% to $31.0 million in 2024, then increased by 3.26% to $32.0 million in 2025.
  • Its last three reported values are $32.0 million in Q3 2025, $30.0 million for Q2 2025, and $27.3 million during Q1 2025.